AI Insight
This multicentre randomised controlled trial conducted in Africa examined whether adding valganciclovir (an antiviral medication) to standard care improved outcomes for HIV-positive infants hospitalised with severe pneumonia. The study found that empirical treatment with valganciclovir was associated with a lower risk of death compared to standard care alone or standard care combined with empirical tuberculosis treatment. The intervention showed safety with little evidence of harmful side effects in this vulnerable population.
Why it matters
This finding could change treatment protocols for HIV-positive infants with severe pneumonia in resource-limited settings, potentially reducing mortality in a high-risk group. The results suggest that cytomegalovirus infection may be an underrecognized contributor to severe pneumonia deaths in infants living with HIV, and that empirical antiviral treatment could be beneficial even without confirmed viral testing.
Understand the Science
Empirical valganciclovir treatment appeared to be associated with a lower hazard of death in infants with severe HIV-associated pneumonia than SOC alone or SOC plus empirical tuberculosis treatment, and there was little evidence of associated harms.